This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
September 30, 2013 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it has established a sponsored Level 1 American Depositary Receipt (ADR) program. Trading of the ADRs commences today on the US over the counter (OTC) market under the ticker TBGNY.
ThromboGenics' ADRs are US dollar negotiable certificates with each ADR representing half of one ordinary share of the Company. J.P. Morgan has been appointed as the depositary bank for the ThromboGenics' ADR program.
ADR effective date: September 30, 2013
Ratio 2 ADRs: 1 Ordinary Share
CUSIP: 886003 10 2
Local ISIN: BE0003846632
Country of incorporation:BelgiumIndustry: Biopharmaceutical
Depositary: JPMorgan Chase Bank, N.A.
Custodian: BNP Paribas,
For questions related to the ThromboGenics ADR Program, please contact J.P. Morgan shareholder services:
J.P. Morgan Depositary Bank
1 Chase Manhattan Plaza, Floor 58
New York, NY 10005
In the U.S.: (866) JPM-ADRS
Outside the U.S.: (+1 866 576-2377)
Or visit J.P. Morgan Depositary Receipts Services at
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA
® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in
ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA
the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA
®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA
® for a number of new vitreoretinal indications.
® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA
® in the UK,
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403.